L3VLUP
ProSign in

ARVN in the 13F filings

Arvinas Inc · CUSIP 04335A105

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023
Quarter end
30 Sep 2023
the date the book describes
Filed
14 Nov 2023
latest of these filings; the earliest 14 Nov 2023
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2023 and Q3 2023; 2 listed it in both
Shares listed
237,716
combined, among listed positions
Reported value
$4.7m
combined, at the quarter end

Managers listing ARVN in Q3 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
Woodline Partners LP172,600$3.4munder 0.1%Added+60,00014 Nov 2023 (the filing on sec.gov)
PDT Partners LLC65,116$1.3m0.16%Added+13414 Nov 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2023 to Q3 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q2 2024 to 1 in Q2 2026

Tracked managers listing it, at least.

02468202020212022202320242026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
ARVN by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20194$21mn.a.n.a.
Q3 20191$10mn.a.n.a.
Q4 20192$21mn.a.n.a.
Q1 20202$27mn.a.n.a.
Q2 20205$43mn.a.n.a.
Q4 20208$615mn.a.n.a.
Q1 20215$162mn.a.n.a.
Q2 20216$639mn.a.n.a.
Q3 20215$693mn.a.n.a.
Q4 20214$644mn.a.n.a.
Q1 20222$542mn.a.n.a.
Q2 20222$20mn.a.n.a.
Q3 20223$107mn.a.n.a.
Q4 20222$1.1mn.a.n.a.
Q1 20232$2.2mn.a.n.a.
Q2 20232$4.4mn.a.n.a.
Q3 20232$4.7mn.a.n.a.
Q4 20236$229m51
Q1 20245$227m50
Q2 20243$22m22
Q3 20242$21m20
Q4 20242$26m20
Q2 20253$19m30
Q3 20252$18m20
Q4 20252$19m1414
Q1 20261$2.8m916
Q2 20261$684k1414

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

ARVN and LLY →ARVN and JNJ →ARVN and VRTX →Choose a stock to compare with ARVN →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own ARVN, latest filings →Back to the 13F Explorer →